---
title: "Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290103200.md"
description: "Polyrizon Ltd. announced the U.S. publication of its patent application for mucoadhesive polymers used in nasal drug delivery, covering its proprietary 'Trap & Target' platform. This technology aims to enhance drug retention and absorption via biocompatible hydrogels. The company, a development-stage biotech focused on nasal spray barriers and active ingredient delivery, currently has a market cap of $19.31M with a 'Sell' technical sentiment."
datetime: "2026-06-17T20:28:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290103200.md)
  - [en](https://longbridge.com/en/news/290103200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290103200.md)
generator: "portal-rs"
---

# Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent

An update from Polyrizon Ltd. ( (PLRZ) ) is now available.

On June 17, 2026, Polyrizon Ltd. announced that its U.S. patent application for mucoadhesive polymers for nasal drug delivery has been published, covering its proprietary Trap & Target platform. The technology is designed to enhance interaction with nasal mucosa, improving retention, absorption and efficient intranasal delivery of drugs through biocompatible, film-forming hydrogel compositions.

The published application details formulations that combine sulfated polysaccharides, hydrophilic polymers and divalent ions to optimize viscosity, sprayability and film formation on mucosal surfaces. It also outlines potential applications across nasal and oral sprays, gels and inhalation products for localized and systemic delivery of therapies such as anti-inflammatory drugs, vaccines and biologics, underscoring Polyrizon’s push to broaden its drug delivery capabilities.

**More about Polyrizon Ltd.**

Polyrizon Ltd. is a development-stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, aimed at forming a thin hydrogel-based barrier in the nasal cavity to protect against viruses and allergens. Its core Capture and Contain (C&C) technology functions as a “biological mask,” while the company is also advancing Trap and Target (T&T), an early-stage platform for intranasal delivery of active pharmaceutical ingredients.

**Average Trading Volume:** 42,730

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $19.31M

Find detailed analytics on PLRZ stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [PLRZ.US](https://longbridge.com/en/quote/PLRZ.US.md)

## Related News & Research

- [Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement | PLRZ Stock News](https://longbridge.com/en/news/298058479.md)
- [Bank of America lifts Delivery Hero voting rights stake to 5.13% from 4.38%](https://longbridge.com/en/news/298736023.md)
- [AECOM and Jacobs joint venture appointed program delivery partner for MetroLink | ACM Stock News](https://longbridge.com/en/news/298610570.md)
- [medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector | MDMXF Stock News](https://longbridge.com/en/news/298551232.md)
- [AstraZeneca's breast cancer drug fails in late-stage trial](https://longbridge.com/en/news/298768423.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**